Loading
IDP-004 is an experimental bispecific antibody-drug conjugate from InduPro Therapeutics, in preclinical development for cancer.
IDP-004 is a bispecific antibody-drug conjugate from InduPro Therapeutics. A bispecific antibody-drug conjugate against MET and an undisclosed partner antigen the company calls TAPA-M1. Its furthest stage is preclinical development, for cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Pipeline chart bar ends in the lead-optimisation column (HTML data-width 48); no registered trial found. It has not been shown to work in people.
A bispecific antibody-drug conjugate against MET and an undisclosed partner antigen the company calls TAPA-M1. Connects to MET.
1.IDP-004's antibody arm binds MET on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"IDP-004" OR ABSTRACT:"IDP-004") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IDP-004, not a curated reading list.
Shares InduPro Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares InduPro Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares MET, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/